Quick Answer
Vaxart, Inc. reported Diluted EPS of $0.07 per share for fiscal year 2025.
Vaxart, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $0.07 | +121.2% |
| 2024 | -$0.33 | -6.5% |
| 2013 | -$0.31 | +63.5% |
| 2012 | -$0.85 | +24.1% |
| 2011 | -$1.12 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| March 31, 2019 | -$0.18 | -136.7% | -136.7% |
| March 31, 2018 | $0.49 | +101.9% | +101.9% |
| March 31, 2017 | -$25.84 | -18357.1% | -9838.5% |
| September 30, 2016 | -$0.26 | -52.9% | -85.7% |
| March 31, 2016 | -$0.14 | -566.7% | +17.6% |
| December 31, 2015 | -$0.17 | -189.5% | +0.0% |
| September 30, 2015 | -$0.17 | +15.0% | -666.7% |
| March 31, 2015 | $0.03 | -66.7% | -84.2% |
- Vaxart, Inc. showed an increase of +121.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2011–2025 period, Vaxart, Inc.’s diluted eps has grown by 106.2% (from $1.12 per share (loss) to $0.07 per share).
- The most recent figure is from Vaxart, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: